Moderna reports 83% response rate in Phase 1/2 melanoma trial of mRNA-4359 combo
PUBT · 1d ago
Share
Listen to the news
- Moderna scheduled Phase 1/2 data presentation on investigational cancer antigen therapy mRNA-4359 with pembrolizumab at AACR Annual Meeting on April 20, 2026.
- Early-stage study in first-line locally advanced or metastatic melanoma showed strong tumor-shrinking activity in most patients.
- Responses were reported across tumors with higher or lower PD-L1 expression.
- Safety profile was described as manageable, with no new immune-related side effects flagged.
- FDA granted Fast Track designation for mRNA-4359 with pembrolizumab in checkpoint inhibitor-refractory unresectable or metastatic melanoma with PD-L1+ tumors.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202604171500ACCESSWRNAPR_____1158280) on April 17, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved